Product image of Mycophenolsyre Accord (Mycophenolic Acid) supplied by GNH India

Mycophenolsyre Accord

Active Ingredient:
Mycophenolic Acid
Origin:
EU

Mycophenolsyre Accord (Mycophenolic Acid)

Mycophenolic Acid, the active ingredient in Mycophenolsyre Accord, is an antimetabolite immunosuppressant presented as an oral formulation for oral use. It is employed to reduce the risk of organ transplant rejection and to manage selected autoimmune disorders by inhibiting lymphocyte proliferation. After absorption the drug distributes systemically, achieving therapeutic concentrations that target immune cells while maintaining a favorable pharmacokinetic profile.

GNH India supplies Mycophenolsyre Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Manufacturer / TM Owner

Accord Healthcare B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mycophenolsyre Accord is an antimetabolite immunosuppressant used in conditions where immune modulation is required.

  • Organ transplant rejection: helps prevent acute and chronic rejection episodes after kidney, heart or liver transplantation.
  • Autoimmune disease: used to treat severe manifestations such as lupus nephritis and certain vasculitides.
  • Off‑label severe rheumatoid arthritis: may be considered when conventional disease‑modifying agents are inadequate.

How It Works

  • Mycophenolic Acid selectively inhibits inosine monophosphate dehydrogenase (IMPDH), the key enzyme for guanosine nucleotide synthesis in lymphocytes. By depleting guanosine pools, it suppresses proliferation of T‑ and B‑lymphocytes, thereby reducing immune‑mediated damage while sparing most other cell types.

Side Effects

Adverse reactions may occur with Mycophenolsyre Accord and should be monitored.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Diarrhea: frequent loose stools, may lead to dehydration.
  • Headache: transient cranial discomfort.
  • Tremor: mild shaking of hands or limbs.
  • Infections: increased susceptibility to bacterial, viral or fungal infections.
  • Elevated liver enzymes: mild transaminase rise.

Serious or Rare Side Effects

  • Leukopenia or neutropenia: significant drop in white blood cells.
  • Anemia: reduced red blood cell count.
  • Severe infection: opportunistic or life‑threatening infections.
  • Malignancy: increased long‑term risk of certain cancers.
  • Teratogenicity: potential harm to a developing fetus.
  • Progressive multifocal leukoencephalopathy (PML): rare demyelinating disease.

Precautions & Warnings

Careful monitoring and patient education are essential when using Mycophenolsyre Accord.

  • Monitor blood counts: regular CBC to detect leukopenia or anemia.
  • Assess renal function: dose may need adjustment in renal impairment.
  • Avoid live vaccines: increased risk of vaccine‑derived infection.
  • Pregnancy risk: discuss potential teratogenic effects and consider alternative therapy.
  • Hepatic monitoring: check liver enzymes periodically.
  • Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Mycophenolsyre Accord can interact with several medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid)

  • Azathioprine: combined use markedly increases myelosuppression.
  • Live vaccines: heightened risk of vaccine‑associated infection.

Moderate Interactions (Monitor Closely)

  • Cyclosporine or tacrolimus: may raise mycophenolic acid exposure, requiring dose adjustment.
  • Cholesterol‑binding resins (e.g., cholestyramine): can reduce absorption of mycophenolic acid.
  • Warfarin: may potentiate anticoagulant effect, monitor INR.
  • Antacids containing aluminum or magnesium: may interfere with drug absorption.

Frequently Asked Questions

Mycophenolsyre Accord contains mycophenolic acid, an antimetabolite immunosuppressant. It is prescribed to prevent organ transplant rejection and to treat selected autoimmune diseases such as lupus nephritis, where suppression of T‑ and B‑cell activity is required.

Mycophenolic acid blocks the enzyme inosine monophosphate dehydrogenase (IMPDH), which is essential for guanosine nucleotide synthesis in lymphocytes. This inhibition depletes guanosine pools, halting proliferation of T‑ and B‑cells and thereby dampening the immune response.

The specific dose of Mycophenolsyre Accord is determined by the prescribing clinician based on the patient’s condition, organ function, and concomitant therapies. Dosage regimens are individualized and should follow the prescriber’s instructions.

Safety data for mycophenolic acid in pregnancy are limited, and the drug may pose a risk to the fetus. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternative treatments with their healthcare provider.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with calcineurin inhibitors such as cyclosporine, mycophenolic acid offers a different mechanism—targeting nucleotide synthesis rather than calcineurin signaling. It is often used in combination regimens to provide synergistic immunosuppression while allowing lower doses of each agent.

Mycophenolsyre Accord should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, excessive heat and direct sunlight to maintain stability.

The medication is taken orally, usually as a tablet or capsule, with or without food as directed by the prescriber. Swallow the dose whole; do not crush or split unless instructed by a healthcare professional.

Serious risks include severe bone‑marrow suppression (leukopenia, neutropenia, anemia), opportunistic infections, potential malignancy, and teratogenic effects. Patients should be monitored regularly for blood‑cell counts, signs of infection and liver function.

Patients with known hypersensitivity to mycophenolic acid or any component of the formulation should avoid the drug. It is also contraindicated in individuals with uncontrolled severe infections, active malignancy, or in whom the risk‑benefit ratio is unfavorable, such as certain pregnant women.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mycophenolic Acid

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT